This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Subacute cerebellar ataxia in patients with cancer in whom metastasis to the cerebellum has not occurred and who exhibit neither infection, side effects of chemotherapy, nor nutritional deficiencies, is designated paraneoplastic cerebellar degeneration (PCD). A group of women with PCD and ovarian or uterine cancer harbor an anti-Yo antibody in their sera and CSF.1 Anti-Yo antibody binds to 52- to 62-kD and 34-kD proteins on Western blots of human Purkinje cell extracts and reacts with Purkinje and other neuronal cell cytoplasm on immunohistochemical analysis. This antibody may be produced against tumor antigens that also react with neuronal proteins. However, there is no evidence that anti-Yo antibody causes neuronal damage. We have failed in numerous attempts to produce animal models of PCD by injection of serum IgG from patients with PCD into rodent brains or by immunization of rodents with recombinant Yo protein; neuronal degeneration was not induced in any of these cases.2 However, the sera of PCD patients could contain minor antibodies …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
